Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease (Q43039307)

From Wikidata

Jump to navigation Jump to search

scientific article published on 10 June 2010

Language	Label	Description	Also known as
English	Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease	scientific article published on 10 June 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Lazaros I Sakkas

5

object named as

Lazaros I Sakkas

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

author name string

Athanasios Koutroumpas

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Athanasios Ziogas

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Ioannis Alexiou

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Georgia Barouta

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

publication date

10 June 2010

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Clinical Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1167-1168

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20532938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20532938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20532938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of D-penicillamine on pulmonary findings in systemic sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20532938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20532938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20532938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20532938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imatinib for the treatment of refractory, diffuse systemic sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20532938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Changes in causes of death in systemic sclerosis, 1972-2002

1 reference

https://pubmed.ncbi.nlm.nih.gov/20532938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20532938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20532938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Severe restrictive lung disease in systemic sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20532938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis. Prospective study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20532938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclophosphamide versus placebo in scleroderma lung disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20532938

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10067-010-1498-Z

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43039307&oldid=1978306618"